Q-Line Biotech Limited

(iii) HIV-Syphilis Duo Antibody;
(iv) HBsAg
(v) HCV Antibody
(vi) Syphilis Antibody
(vii) Malaria PF/PV Antigen
(viii) Malaria PF/PAN Antigen
(ix) Dengue NS1 Antigen
(x) Dengue Combo (Ag-Ab)
(xi) One Step Novel Coronavirus (COVID-19) IgG Ab Test

ii. Applications made by the Company for the premises situated at Plot No. 3, Pocket H, Sector - 5, DSIIDC, Bawana Industrial Area, New Delhi, Delhi (India) â€“ 110039.

a. The Company has filed an application (Form MD-3) dated August 05, 2025 bearing transaction id 8315932097433/6177893757929. for Grant of Licence to Manufacture for Sale and Distribution of Class A or Class B medical device which are as under:

(i) Adenosine Deaminase Assay (ADA)
(ii) Albumin
(iii) ALP (DEA)
(iv) ALP (IFCC)
(v) ALT/GPT
(vi) Amylase
(vii) ASO Turbilatex
(viii) Apolipoprotein A1
(ix) Apolipoprotein B
(x) ASO Latex
(xi) AST/GOT
(xii) Bilirubin Total
(xiii) Bilirubin T&D
(xiv) Calcium Arsenazo
(xv) Chloride
(xvi) CK-NAC
(xvii) Cholesterol
(xviii) CK-MB
(xix) Creatinine Jaffe
(xx) Creatinine PAP
(xxi) CRP Latex
(xxii) CRP Turbilatex
(xxiii) Cystatin C
(xxiv) HbA1c Direct
(xxv) Vitamin D

b. The Company has filed an application (Form MD-3) dated August 08, 2025 bearing transaction id 1902813598146 for Grant of Licence to Manufacture for Sale and Distribution of Class A or Class B medical device which are as under:

(i) Ferritin
(ii) Gamma-GT
(iii) Glucose PAP
(iv) Glycated Serum Protein
(v) Cholesterol (Direct)
(vi) Homocysteine
(vii) High Sensitive C-Reactive Protein (hs-CRP)
(viii) Iron
(ix) Lactate
(x) LDH-P
(xi) LDL Cholesterol (Direct)
(xii) Lipase
(xiii) Lipo Protein (a)
(xiv) Magnesium Xylidyl
(xv) Phosphorus
(xvi) RF-Latex
(xvii) RF-Turbilatex
(xviii) Total Iron Binding Capacity (TIBC)